

# PILULKA LEKARNY A.S. NPV

ISIN: CZ0009009874 WKN: - Asset Class: **Stock**

## Company

2024/04/30 15:01:05

Price

**180.00**

CZK

Difference

**0.84%**(1.50)



## Contact Details

PILULKA LÉKÁRNY AS

Tel: +420-222-703-000

--

Fax: +

Drahobejlova 1073/36,  
Liben

Web: <http://www.pilulka-lekarny.cz>

190 00 Prague

E-mail: [info@pilulka.cz](mailto:info@pilulka.cz)

## Company Profile

Pilulka Lékárny as operates retail and online pharmacy stores. The firm focuses on online sale of pharmacy and related goods and services under the Pilulka brand in the Czech Republic, Slovakia and Romania. The company was founded by Petr Kasa and Martin Kasa in 2013, and is headquartered in Praha, Czech Republic.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2022        |                        | 2021        |                        | 2020        |                        |
|---------------------------------------|-------------|------------------------|-------------|------------------------|-------------|------------------------|
|                                       | Assets      | Liabilities and equity | Assets      | Liabilities and equity | Assets      | Liabilities and equity |
| <b>Current assets</b>                 | 407,952,000 |                        | 410,971,000 |                        | 378,008,000 |                        |
| <b>Common stock capital</b>           |             | 2,521,000              |             | 2,500,000              |             | 2,500,000              |
| <b>Fixed assets</b>                   | 221,619,000 |                        | 204,065,000 |                        | 147,868,000 |                        |
| <b>Equity capital of a company</b>    |             | 138,933,000            |             | 204,101,000            |             | 218,055,000            |
| <b>Cash and cash equivalents</b>      | 20,673,000  |                        | 71,607,000  |                        | 131,781,000 |                        |
| <b>Accrued liabilities</b>            |             | 8,461,000              |             | 14,967,000             |             | 5,622,000              |
| <b>Other assets</b>                   | -           |                        | -           |                        | -           |                        |
| <b>Current liabilities</b>            |             | 433,643,000            |             | 348,615,000            |             | 271,096,000            |
| <b>Prepayments and accrued income</b> | -           |                        | -           |                        | -           |                        |
| <b>Non-current liabilities</b>        |             | 56,995,000             |             | 62,320,000             |             | 36,725,000             |
| <b>Different income</b>               |             | -                      |             | -                      |             | -                      |
| <b>Other liabilities</b>              |             | 23,608,000             |             | 25,900,000             |             | 27,897,000             |
| <b>Total assets</b>                   | 629,571,000 | 629,571,000            | 615,036,000 | 615,036,000            | 525,876,000 | 525,876,000            |

## Balance notes

|                            | 2022    | 2021    | 2020    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS    |
| <b>Employees</b>           | 383     | 363     | 285     |
| <b>Equity ratio</b>        | 21.88%  | 33.14%  | 39.61%  |
| <b>Debt-equity ratio</b>   | 357.12% | 201.75% | 152.44% |

## Others

|                         | 2022   | 2021   | 2020   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | -2.73% | -4.03% | -2.19% |

# PILULKA LEKARNY A.S. NPV

ISIN: CZ0009009874 WKN: - Asset Class: **Stock**

## Income statement

|  | 2022          | 2021          | 2020          |
|--|---------------|---------------|---------------|
| <b>Turnover</b>  | 2,447,298,000 | 2,380,297,000 | 1,780,216,000 |
| <b>Net income</b>  | -64,938,000   | -25,495,000   | -21,857,000   |
| <b>EBIT</b>  | -1,903,714    | -541,957      | -635,049      |
| <b>Operating income before taxes</b>                                 | -64,011,000   | -24,676,000   | -25,093,000   |
| <b>Cash Flow</b>   | -38,149,000   | 24,670,000    | 7,390,000     |
| <b>Net interest income</b>   | -16,179,000   | -11,059,000   | -9,137,000    |
| <b>Research and development expenses</b>                             | 0             | 0             | 0             |
| <b>Income taxes</b>  | 1,747,000     | 994,000       | 549,000       |
| <b>Result from investments in subsidiaries, associates and other</b> | 0             | 0             | 0             |
| <b>Revenues per employee</b>   | 254,315       | 260,980       | 248,606       |

## Board of Directors

|                 |                               |
|-----------------|-------------------------------|
| Martin Buchta   | Chairman of Supervisory Board |
| Marek Krajcovic | Member of Supervisory Board   |
| Miloš Cebík     | Member of Supervisory Board   |

## Members of Management Board

|             |                               |
|-------------|-------------------------------|
| Martin Kasa | Member of Executive Committee |
| Petr Kasa   | Member of Executive Committee |